Dermatomyositis   

Questions discussed in this category


Given the lack of efficacy of most treatment options, do you generally try to treat calcinosis cutis that is not bothering the patient even if it is q...

If so, what dose-fractionation do you utilize? What other factors do you take into consideration?

Do you taper one DMARD as you uptitrate another versus do you stop the first DMARD and quickly uptitrate another one?

Will you still favor starting with steroids and traditional immunosuppressive agents, move IVIG earlier in your treatment strategy, or start with IVIG...

For example, in the setting of cirrhosis incidentally found on imaging.

Is there a role of immunosuppression or treating underlying malignancy will be enough?

Any indications for triple therapy in the patients with subclinical ILD associated with MDA-5 dermatomyositis?


Papers discussed in this category


,

, 2016 Aug 30

N Engl J Med, 2022 Oct 06

Minerva Gastroenterol Dietol, 2016 Sep 07

Free Radic Biol Med,

Rheum Dis Clin North Am, 2020 Aug

Rheumatology (Oxford),

The British journal of dermatology, 2019-11

Frontiers in immunology, 2019

J Am Acad Dermatol, 2020 Sep 04

Rheumatology (Oxford),

The New England journal of medicine, 1993-12-30